KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Net Margin (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Net Margin for 16 consecutive years, with 31.34% as the latest value for Q4 2025.

  • Quarterly Net Margin fell 7732.0% to 31.34% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 22.69% through Dec 2025, down 2104.0% year-over-year, with the annual reading at 22.69% for FY2025, 2105.0% down from the prior year.
  • Net Margin for Q4 2025 was 31.34% at Halozyme Therapeutics, down from 49.47% in the prior quarter.
  • The five-year high for Net Margin was 186.99% in Q3 2021, with the low at 31.34% in Q4 2025.
  • Average Net Margin over 5 years is 44.88%, with a median of 39.76% recorded in 2024.
  • The sharpest move saw Net Margin skyrocketed 13155bps in 2021, then crashed -15749bps in 2022.
  • Over 5 years, Net Margin stood at 65.46% in 2021, then tumbled by -51bps to 31.79% in 2022, then grew by 17bps to 37.12% in 2023, then rose by 24bps to 45.98% in 2024, then tumbled by -168bps to 31.34% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 31.34%, 49.47%, and 50.71% for Q4 2025, Q3 2025, and Q2 2025 respectively.